3 Analyst-Backed Pharmaceutical Stocks With Great Projections

|
 |  Includes: AEGR, KERX, RIGL
by: ZetaKap

For investors specifically interested in keeping tabs on the pharmaceutical industry, checking in with the latest news from analysts can be a helpful tool in finding new opportunities. Today, we have a quick list of pharmaceutical stocks that have been recently noted to be a 'Buy' or 'Strong Buy' by analysts. Additionally, all of these companies met the high-growth projection requirements. Take a look at the list below to begin your research process.

EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. The 1-Year Expected EPS Growth Rate is an annual growth estimate, where the growth projections are made by analysts, the company or other credible sources.

We first looked for pharmaceutical stocks. From there, we looked for companies that analysts rate as "Buy" or "Strong Buy" (mean recommendation <3). We then looked for companies that have high future earnings per share growth forecasts (1-year projected EPS Growth Rate >25%). We did not screen out any market caps.

Do you think these stocks have strong operations? Use this list as a starting-off point for your own analysis.

1) Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $321.18M
Beta: -
Click to enlarge

Aegerion Pharmaceuticals, Inc. has Analysts' Rating of 1.60 and a 1-Year Projected Earnings Per Share Growth Rate of 45.10%. The short interest was 5.94% as of 07/30/2012. Aegerion Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood.

2) Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $129.57M
Beta: 3.20
Click to enlarge

Keryx Biopharmaceuticals Inc. has Analysts' Rating of 1.40 and a 1-Year Projected Earnings Per Share Growth Rate of 27.80%. The short interest was 14.65% as of 07/30/2012. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Zerenex is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease on dialysis.

3) Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $797.38M
Beta: 1.48
Click to enlarge

Rigel Pharmaceuticals, Inc. has Analysts' Rating of 1.70 and a 1-Year Projected Earnings Per Share Growth Rate of 26.10%. The short interest was 6.85% as of 07/30/2012. Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase III clinical trials for rheumatoid arthritis; R343, an inhaled SYK inhibitor, which completed Phase I clinical trials for asthma; R333, a topical JAK/SYK inhibitor, which is in Phase I clinical trials for the treatment of discoid lupus; and R548, an oral janus kinase 3 (JAK3) inhibitor that in Phase I clinical trials for the treatment of transplant rejection and other immune disorders. The company's research/preclinical programs comprise R348, a soluble JAK/SYK inhibitor for topical ophthalmic use; R256, an inhaled interleukin 13 signaling inhibitor for chronic asthma; an oral activator of adenosine monophosphate activated protein kinase for enhancing the body's energy utilization and restore muscle endurance in chronically ill subjects; and growth/differentiation factor 8 inhibitor to prevent muscle loss.

*Company profiles were sourced from Finviz. Financial data was sourced from Finviz and Google Finance.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.